lunes, 4 de mayo de 2026

TCCC GUIDELINES 2026

Master Technical-Operational Document for Blog Publication

CoTCCC / Joint Trauma System / DoD — 01 MAY 2026
Critical SOMA 2026 Integration | By DrRamonReyesMD ⚕️

Executive Verdict

The Tactical Combat Casualty Care (TCCC) Guidelines 2026 do not redefine MARCH. They refine its execution under real combat stress, prolonged evacuation, and Prolonged Casualty Care (PCC) conditions.

The 2026 shift is not “more protocol.” It is:

Less automatic treatment.
More physiological decision-making.

Core corrections include:

TBI hypoxia and hypotension
Tourniquet reassessment and conversion
Reduced opioid-centric analgesia
Introduction of peripheral/non-opioid analgesia
Ketamine safety refinement
Avoidance of harmful polypharmacy
Tier 4 sedation as true dissociative anesthesia
Antibiotic simplification for austere logistics
PCC realism when evacuation is not guaranteed

Official TCCC 2026 PDF:
https://learning-media.allogy.com/api/v1/pdf/18ccfdfc-a076-47e9-8a34-376efdd81b43/contents

CoTCCC / JTS:
https://jts.health.mil/index.cfm/committees/cotccc

Deployed Medicine:
https://deployedmedicine.com

1. The Real Doctrinal Shift

TCCC 2026 moves the provider from passive protocol execution to active physiological reassessment.

The modern tactical provider must:

Control hemorrhage
Reassess tourniquets
Protect brain oxygenation and perfusion
Ventilate with targets
Treat pain without compromising airway or breathing
Avoid respiratory-depressant polypharmacy
Prepare for prolonged casualty survival when evacuation is delayed

Operational message: the modern error is not only “not knowing what to do.”
It is failing to know when the previous intervention must be changed.

2. Care Under Fire / Threat

The Care Under Fire / Threat phase remains structurally unchanged.

The priority remains:

Return fire
Take cover
Direct the casualty to self-aid if possible
Move the casualty to cover
Prevent additional injuries
Control life-threatening hemorrhage if tactically feasible

DrRamonReyesMD interpretation: in Care Under Fire, the best medical intervention may be tactical dominance, cover, and preventing the rescuer from becoming the next casualty.

3. Hemorrhage Control: Dynamic Tourniquet Management

The tourniquet is no longer treated as a “place and forget” intervention. TCCC 2026 reinforces reassessment, repositioning, and conversion when appropriate.

Key actions include:

Expose the wound
Determine whether the tourniquet is still needed
Place a second tourniquet directly on skin, 2–3 inches proximal to the bleeding site, before loosening the first
Confirm bleeding control
Check distal pulse when appropriate

Tourniquet conversion should only be considered when:

The casualty is not in shock
Bleeding can be controlled by alternative means
Monitoring is possible
The injury is not a traumatic amputation

Drew, Bird, Matteucci, and Keenan support a systematic tourniquet conversion approach in the Prolonged Field Care setting. DOI: 10.55460/IJ9C-6AIF.
https://pubmed.ncbi.nlm.nih.gov/26360360/

Correct interpretation: “tourniquet conversion for everyone” does not mean anyone should remove tourniquets casually. It means controlled expansion of the concept under training, criteria, and tactical judgment.

The tourniquet saves the life in the first minutes.
Reassessment may save the limb in the following hours.

4. TBI: The Neuroprotective Core of TCCC 2026

The most important physiological change is in moderate/severe traumatic brain injury.

TCCC 2026 targets:

SpO₂ ≥ 92%
Systolic blood pressure >100 mmHg, or normal radial pulse if blood pressure cannot be measured
EtCO₂ 35–45 mmHg when ventilated and capnography is available

The guideline recommends supplemental oxygen to maintain SpO₂ ≥92% in moderate/severe TBI and warns that pulse oximetry may be misleading in shock or marked hypothermia.

The Brain Trauma Foundation supports aggressive avoidance of hypoxia and hypotension in severe TBI. DOI: 10.1227/NEU.0000000000001432.
https://pubmed.ncbi.nlm.nih.gov/27654000/

Clinical interpretation: SpO₂ 90–91% may look “acceptable” in stable civilian settings, but in combat TBI with shock, cold exposure, vasoconstriction, movement, or poor signal, it may represent dangerous cerebral oxygenation.

5. Ventilation and EtCO₂: Ventilation Becomes Brain Therapy

Target EtCO₂:

35–45 mmHg

This avoids two classic errors:

Hypoventilation → hypercapnia → increased intracranial pressure
Reflex hyperventilation → hypocapnia → cerebral vasoconstriction and ischemia

When EtCO₂ is unavailable, the practical guidance remains controlled low-volume ventilation, avoiding blind aggressive bagging.

Doctrinal statement:

In TBI, ventilation is not passive support.
It is active brain treatment.

6. Advanced TBI: Intracranial Pressure, Herniation, and Penetrating Injury

TCCC 2026 includes practical measures for suspected increased intracranial pressure:

Elevate head and torso >30° when tactically feasible and if not in shock
Avoid cervical venous compression
Maintain the head in a neutral position
Reassess neurological status every 5–10 minutes

For suspected herniation, hypertonic saline may be used:

3% or 5% NaCl: 250 mL
23.4% NaCl: 30 mL IV/IO over at least 10 minutes
Repeat only if no response, maximum two doses

Important restrictions:

Do not use hypertonic saline prophylactically
Do not use it as resuscitation fluid

For penetrating TBI or open skull fracture:

Cover the exposed area
Do not pack material into the cranial cavity
Do not close with staples or sutures in the field
Irrigate gently if contaminated
Administer antibiotics according to TCCC guidance

7. Resuscitation: Whole Blood, TXA, and Avoiding Crystalloid Overload

A serious master document must strengthen resuscitation.

Modern combat resuscitation rests on three pillars:

Whole blood / blood products

TCCC emphasizes early transfusion after life-threatening hemorrhage. If Rh-negative products are not immediately available, Rh-positive products may be used in hemorrhagic shock when clinically necessary. Fresh whole blood or type-specific fresh blood carries hemolytic reaction risks and should be administered under appropriate medical direction and by trained personnel.

Tranexamic acid (TXA)

TXA should be considered in significant hemorrhage or risk of massive bleeding, particularly within the first 3 hours after injury.

CRASH-2 showed reduced death due to bleeding when TXA was given early in trauma. DOI: 10.1016/S0140-6736(10)60835-5.
https://pubmed.ncbi.nlm.nih.gov/20554319/

The MATTERs military study observed improved survival and coagulopathy outcomes in combat casualties receiving TXA with blood-component resuscitation.
https://pubmed.ncbi.nlm.nih.gov/22006852/

Crystalloids

Large-volume crystalloids should be avoided in hemorrhagic trauma when blood products are needed. Excess crystalloid can dilute clotting factors, worsen hypothermia, and aggravate coagulopathy.

Operational goal: do not “fill the patient.” Restore enough perfusion while prioritizing hemorrhage control and blood-based resuscitation.

8. Analgesia 2026: Reduced Opioid Dominance, Not Opioid Elimination

A critical correction is needed: TCCC 2026 does not eliminate opioids entirely. The correct interpretation is that it reduces opioid dominance and reinforces multimodal analgesia that protects airway, breathing, cognition, and prolonged evacuation safety.

The Combat Wound Medication Pack concept includes:

Acetaminophen/paracetamol
Meloxicam
Suzetrigine

For casualties unable to continue the mission, the analgesia pathway includes ketamine IM, IN, or slow IV/IO, and esketamine IN under appropriate conditions.

SOMA 2026 interpretation: the operational shift is not “kill all narcotics.” It is reducing dependence on respiratory-depressant analgesia and increasing use of non-opioid, peripheral, and multimodal options when tactically appropriate.

9. Suzetrigine: Real Innovation, Limited Global Applicability

Suzetrigine is a non-opioid analgesic targeting the NaV1.8 sodium channel, relevant to peripheral nociceptive signaling.

The FDA approved suzetrigine in 2025 for moderate-to-severe acute pain in adults.
https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain

Phase 3 trials published in Anesthesiology showed efficacy in controlled postoperative pain models such as abdominoplasty and bunionectomy. DOI: 10.1097/ALN.0000000000005460.
https://pubmed.ncbi.nlm.nih.gov/40117446/

Critical limitation: suzetrigine should not be presented as a global standard. Its 2026 operational availability outside the U.S. ecosystem is limited. In Spain, Portugal, Italy, and other European settings, it may not be routinely available or integrated into military/EMS logistics.

European adaptation: potential alternatives should be framed as local logistical adaptations, not direct pharmacological equivalents:

Paracetamol
NSAIDs available under local protocol
Analgesic-dose ketamine
Regional anesthesia when provider level and environment permit
Dexketoprofen where available and protocol-approved

Key statement: suzetrigine is a meaningful doctrinal signal toward peripheral, non-opioid analgesia, but it is not yet a universal operational solution.

10. Ketamine: Essential Tool, Not a Magical Totem

Ketamine remains central in tactical analgesia because it provides powerful analgesia, dissociation when needed, relative hemodynamic stability, and less respiratory depression than many sedatives.

TCCC 2026 emphasizes:

Document AVPU before administration
Monitor airway, breathing, and circulation after potent analgesics
Use high concentration for intranasal dosing to reduce volume
Administer IV/IO slowly over approximately 1 minute
It is generally safe to administer ketamine after prior opioid use, but monitoring remains mandatory

Important risks:

Reduced respirations
Laryngospasm, rare but critical
Airway obstruction due to positioning or secretions
Hypoventilation after dosing

The TCCC analgesia and sedation review discusses the evolution of tactical analgesia and ketamine use.
https://pubmed.ncbi.nlm.nih.gov/35639907/

Clinical statement: ketamine does not replace competence. It demands it.

11. Benzodiazepines: Avoid Depressant Polypharmacy

TCCC 2026 discourages routine benzodiazepine coadministration with ketamine, esketamine, or opioids. Polypharmacy in the field can depress ventilation, obscure neurological assessment, worsen evacuation, increase aspiration risk, and convert a pain problem into an airway problem.

If the casualty appears partially dissociated, additional ketamine may be safer than adding a benzodiazepine.

Midazolam should be reserved for severe emergence phenomena in advanced settings, not used as routine premedication.

12. Tier 4 Sedation: Operational Dissociative Anesthesia

The Tier 4 / SOCM / Combat Paramedic sedation block is one of the most important parts of the 2026 update.

This is not analgesia.
It is procedural dissociative anesthesia in a tactical environment.

Indications include:

Severe injury requiring dissociation
Casualty safety
Mission success
Invasive procedures

Initial ketamine dosing:

1–2 mg/kg IV/IO slow bolus
300 mg IM or 2–3 mg/kg IM

Endpoint:

Procedural dissociative anesthesia

Mandatory condition:

The provider must be prepared to secure the airway.

This means real airway rescue capability:

Assisted ventilation
Supraglottic airway devices
Endotracheal intubation when indicated and within scope
Surgical cricothyrotomy when airway failure occurs
SpO₂ and EtCO₂ monitoring when available

Midazolam 0.5–2 mg IV/IO may be considered only for severe emergence phenomena.

If continued dissociation is needed, the patient transitions into PCC analgesia and sedation guidance.

DrRamonReyesMD statement:

Sedating without the ability to rescue the airway is not advanced medicine.
It is active iatrogenesis.

13. Antibiotics: Logistical Simplification with Microbiological Rationale

TCCC 2026 simplifies antibiotics for combat wounds and invasive procedures.

If the casualty can take oral medication:

Cefadroxil 1 g PO once daily
Or cephalexin 500 mg PO every 6 hours

If the casualty cannot take oral medication due to shock, unconsciousness, or inability to swallow:

Ceftriaxone 2 g IV/IO/IM once daily

The 2025 TCCC antibiotic change reviewed current options, multidrug resistance, combat wound microbiology, adverse effects, stability, dosing, cost, and availability. DOI: 10.55460/SW7X-X8ZP.
https://pubmed.ncbi.nlm.nih.gov/41474877/

Correct interpretation: this is not antibiotic fashion. It is operational simplification: availability, stability, spectrum, cost, safety, and ease of administration during prolonged evacuation.

14. Penetrating Eye Trauma

Key actions:

Rapid visual acuity test if possible
Document findings
Cover with rigid eye shield
Do not apply pressure
Give early antibiotics

Suggested antibiotic pathway in the visible material includes ceftriaxone 2 g IV/IM or cefadroxil 1 g PO as early as possible.

Critical error: compressing an open globe can extrude intraocular contents and convert a severe but potentially salvageable injury into irreversible blindness.

15. Real PCC: 24–72 Hours, Degraded Logistics, Limited Monitoring

PCC cannot be mentioned casually. It must be expanded.

Modern conflicts do not guarantee the golden hour. Casualties may remain in austere settings for hours or days, with limited power, limited oxygen, limited personnel, poor visibility, active threat, and uncertain evacuation.

DoD PCC guidance defines prolonged care in austere, remote, expeditionary, or long-distance movement conditions. DOI: 10.55460/8IUQ-907J.
https://pubmed.ncbi.nlm.nih.gov/35278313/

PCC priorities include:

Serial reassessment
Hypothermia prevention
Pain control
Safe ventilation
Intermittent or continuous monitoring depending on resources
Antibiotics
Wound care
Infection prevention
Documentation
Hydration/nutrition when appropriate
Preparation for transfer

Operational concept: survivability must be extended beyond the point of injury.

16. Human Factors: The Missing Piece

TCCC 2026 is not only about equipment and drugs. It is about reducing human error under stress.

Providers fail under:

Cognitive overload
Noise
Fatigue
Threat
Tunnel vision
Anchoring bias
Failure to reassess

The guideline’s practical value lies in forcing repeated checks:

Reassess tourniquets
Confirm perfusion
Confirm oxygenation
Document AVPU
Recheck airway after analgesia
Avoid assuming that the earlier intervention remains correct one hour later

Core message: protocols save lives when executed; reassessment saves lives when the environment changes.

17. Geopolitical and SOMA 2026 Context

The operational relevance of SOMA 2026 is that current conflicts—Ukraine, the Sahel, maritime operations, Middle East theaters, hybrid warfare, and special operations—do not guarantee rapid evacuation.

Therefore, TCCC 2026 must be read as doctrine for physiological survival under uncertainty:

Controlled hemorrhage
Protected brain
Tolerable pain
Safe sedation
Administerable antibiotics
Continuity toward En Route Care and PCC

SOMA-derived interpretation should be framed as professional educational analysis, not as a replacement for CoTCCC/JTS official guidance. The official normative sources remain CoTCCC, JTS, and Deployed Medicine.

Final Corrected Conclusion

The TCCC Guidelines 2026 do not redefine combat medicine. They redefine the clinical responsibility of the operator when evacuation is not guaranteed.

The provider cannot merely apply isolated interventions. He must reassess, correct, anticipate deterioration, and sustain the casualty through an uncertain operational window.

Final operational message: